Contact Us
Drug Search Results
More Filters [+]

Naquotinib

Alternative Names: naquotinib, asp8273
Latest Update: 2022-11-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CYP3A4 Inhibitor,TK Inhibitor,EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Naquotinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SOLAR

P3

Completed

Non-Small-Cell Lung Cancer

2017-12-21

SOLAR

P3

Terminated

Non-Small-Cell Lung Cancer

2017-12-21

8273-CL-0102

P1

Completed

Non-Small-Cell Lung Cancer

2017-07-28

8273-CL-0202

P2

Terminated

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2017-06-09

Recent News Events

Date

Type

Title

11/01/2022

PubMed

 In vitro and in silico growth inhibitory, anti-ovarian & anti-lung carcinoma effects of 1,5 diarylpenta-1,4-dien-3-one as synthetically modified curcumin analogue.

04/01/2022

PubMed

 Analysis to determine the effect of mutations on binding to small chemical molecules.

05/01/2021

PubMed

 Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions